Royalty Report: Medical, Test/Monitoring, Technical Know How – Collection: 28135


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Test/Monitoring
  • Technical Know How
  • Diagnostic Substances
  • Drugs
  • Diagnostic
  • Disease
  • Packaging & Containers
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28135

License Grant
The Licensee entered into a License Agreement with the German Licensor in the field of diagnostic testing and reporting technology.
License Property
The Licensor's device allows the removal of water from almost any biological fluid (urine, saliva and blood) followed by shipment to the laboratory by normal mail at ambient temperatures. There the samples are re-hydrated and determined like normal patient samples.
Field of Use
The Licensee develops and delivers testing and reporting technology and systems, providing service to medical providers.

IPSCIO Record ID: 260378

License Grant
Licensor grants a non-exclusive license, without the right to grant or authorize sublicenses, under the Licensed Patent Rights to develop and perform the Services solely at the Facilities, and to use, and offer for sale and sell the Services to Third Parties solely in the Territory.
License Property
Licensed Patent Rights shall mean, collectively, Licensors rights in all patent applications, including provisional patent applications, heretofore or hereafter filed in the Territory;  all patents that have issued or in the future issue in the Territory from any of such patent applications, including without limitation utility models, design patents and certificates of invention; and,  all divisionals, continuations, continuations-in-part, substitutions, reissues, renewals, extensions, restorations or additions to any such patent applications and patents, in each case that claim, and only to the extent they claim, compositions, uses, methods, equipment, devices and other technology for the use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, obtained from pregnant women for prenatal diagnostic testing by whole genome massively parallel sequencing, used in the performance of the MaterniT21 PLUS Test by Licensors Laboratories as of the Effective Date, or any improvements to such test; provided, however, that the Licensed Patent Rights shall exclude any of the foregoing licensed by a University to Licensor under another agreement.

MatemiT21 PLUS Test shall mean the laboratory-developed test for the non-invasive testing of a plasma sample from a pregnant woman for the detection and diagnosis of prenatal aneuploidy and/or fetal abnormalities by use of cell-free fetal nucleic acids, currently known as the MatemiT21 PLUS test, as performed by Licensors Laboratories.

Field of Use
The Field shall mean the non-invasive detection and diagnosis of prenatal aneuploidy and fetal abnormalities by use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, obtained from pregnant women.
The MaterniT® 21 PLUS test analyzes genetic information that enters your bloodstream from the placenta.  It analyzes the amount of chromosome 21 in fetal DNA picked up from the maternal blood sample. It can detect an increased amount of chromosome 21 material which is associated with trisomy 21 (Down syndrome). It is completely non-invasive as it only involves a blood sample from the mother.

IPSCIO Record ID: 5350

License Grant
Licensor grants an exclusive license under the Patent Rights to manufacture, use and sell Licensed Products throughout the world, including immunity to suit to all Licensee's customers to use and/or sell such Licensed Products purchased from Licensee and subject to this Agreement.
License Property
The agreement relates to patent rights which are directed to the use of a foam material as a saliva collection device and is for the supply of fluid collection devices using foamed materials like HYPOL(R) materials.

Saliva Collector is designed to replace or serve as an alternative to more traditional and invasive sample collection methodologies such as drawing blood which will require to be separated into the two factors, i.e., cells and plasma.

Saliva Sample Collection System
Title of Application, Filing Date, Serial Number
1. Saliva Sample Collection System; filed May 9, 1995, (CIP of 08/239,726 filed May 9, 1994)
2. Saliva Sample Collection System; filed May 9, 1995, PCT/US95/05889

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.